Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 9/20 | 0.47 |
| ▸ | CTSL | P07711 | 7/20 | 0.47 |
| ▸ | CTSB | P07858 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466473 | 0.84 | CTSS (0.52) | CTSSCTSLCTSBCTSKCA12 | |
| SCHEMBL7420756 | 0.80 | LMNA (0.55) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL30757524 | 0.79 | CTSS (0.52) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL18002248 | 0.75 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| Benzyl Phenethylcarbamate SCHEMBL27338403 | 0.74 | LMNA (0.61) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL15289516 | 0.74 | LMNA (0.57) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL1610211 | 0.74 | CTSS (0.55) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL15776825 | 0.73 | CTSS (0.55) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL8149899 | 0.73 | LMNA (0.59) | LMNASMN1; SMN2CTSSCTSLCTSB | |
| SCHEMBL13741500 | 0.73 | SMN1; SMN2 (0.59) | LMNASMN1; SMN2CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | LMNA 1755/4885SMN1; SMN2 4034/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.